Bruce Booth is a partner at Atlas Venture, focusing on the discovery and development of novel medicines and therapeutic platforms. Currently he is the chairman of AvroBio, Kymera Therapeutics, Hotspot Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Unum Therapeutics, and also serves on the boards of Lysosomal Therapeutics and Magenta Therapeutics. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen, and a number of other ventures. Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University. In his free time, Bruce enjoys running, skiing, hiking and fly fishing. He lives in Wellesley, MA and has three wonderful kids.